Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
'Obesity Not Just Cosmetic': Eli Lilly Ready For Weight-Loss Drug Mounjaro Launch In India | Interview
The prevalence of obesity in India was lower than in other countries but now it's increasing, Rachel Batterham, senior vice ...
Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring
Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...
What To Expect When Eli Lilly Reports Q4 Earnings On Thursday?
Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6 ...
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Zacks.com on MSN13h
NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up
Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...
Lexaria Bioscience provides update on ongoing human study GLP-1-H24-4
Lexaria Bioscience (LEXX) provided progress updates on its Phase 1b, 12-week chronic study GLP-1-H24-4 underway in Australia. Lexaria has ...
Hosted on MSN20h
Found vs Calibrate: Which Is Better For Prescription Weight Loss?
Fitness and nutrition gurus like to make weight loss sound easy. But in reality, it’s often incredibly tough to incorporate ...
Hydreight Technologies Expands Telehealth Offerings with Launch of NAD+ Therapy on VSDHOne Platform
Detailed price information for Hydreight Technologies Inc (NURS-X) from The Globe and Mail including charting and trades.